Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Operating Expenses (2019 - 2025)

Biodesix (BDSX) has disclosed Operating Expenses for 7 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 3.43% year-over-year to $1.9 million, compared with a TTM value of $6.7 million through Dec 2025, down 91.71%, and an annual FY2025 reading of $6.7 million, down 5.59% over the prior year.
  • Operating Expenses was $1.9 million for Q4 2025 at Biodesix, up from -$26.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $34.4 million in Q1 2021 and bottomed at -$60.5 million in Q4 2023.
  • Average Operating Expenses over 5 years is $14.0 million, with a median of $22.1 million recorded in 2021.
  • The sharpest move saw Operating Expenses soared 154.84% in 2021, then crashed 357.57% in 2023.
  • Year by year, Operating Expenses stood at $18.9 million in 2021, then grew by 24.3% to $23.5 million in 2022, then plummeted by 357.57% to -$60.5 million in 2023, then skyrocketed by 103.09% to $1.9 million in 2024, then grew by 3.43% to $1.9 million in 2025.
  • Business Quant data shows Operating Expenses for BDSX at $1.9 million in Q4 2025, -$26.5 million in Q3 2025, and $29.7 million in Q2 2025.